Article Details
Retrieved on: 2024-01-17 23:15:09
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article outlines the significant growth in the biologics contract manufacturing market, driven by an increasing shift from small-molecule drugs to biologics, including vaccines and biosimilars. Key industry players, such as WuXi Biologics and Lonza Group, focus on meeting healthcare needs while adhering to regulations like the FDA's guidelines. This market is expanding with a CAGR of 8.6%, signaling a strong business strategy shift in the pharmaceutical industry, specifically in India and China.
Article found on: finance.yahoo.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here